Precision Medicine in Breast Cancer: Do MRI Biomarkers Identify Patients Who Truly Benefit from the Oncotype DX Recurrence Score<sup>®</sup> Test?

Precision Medicine in Breast Cancer: Do MRI Biomarkers Identify Patients Who Truly Benefit from the Oncotype DX Recurrence Score<sup>®</sup> Test?

The aim of this study was to combine breast MRI-derived biomarkers with clinical-pathological parameters to identify patients who truly need an Oncotype DX Breast Recurrence Score<sup>®</sup> (ODXRS) genomic assay, currently used to predict the benefit of adjuvant chemotherapy in ER-posi...

Full description

Bibliographic Details
Main Authors:	Francesca Galati, Valentina Magri, Giuliana Moffa, Veronica Rizzo, Andrea Botticelli, Enrico Cortesi, Federica Pediconi
Format:	Article
Language:	English
Published:	MDPI AG 2022-11-01
Series:	Diagnostics
Subjects:	early breast cancer multiparametric MRI MRI biomarkers oncotype DX recurrence score genomic assays adjuvant therapy
Online Access:	https://www.mdpi.com/2075-4418/12/11/2730

Similar Items

Spotlight on the utility of the Oncotype DX® breast cancer assay
by: Siow ZR, et al.
Published: (2018-02-01)

Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010–2016
by: Thomas M. Schwedhelm, et al.
Published: (2020-09-01)

The impact of Oncotype DX testing on adjuvant chemotherapy decision making in 1–3 node positive breast cancer
by: Yogeshkumar Malam, et al.
Published: (2022-08-01)

Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score® Test in Node-Negative Early Breast Cancer
by: Berdunov V, et al.
Published: (2022-09-01)

The concordance of treatment decision guided by OncotypeDX and the PREDICT tool in real‐world early‐stage breast cancer
by: Daniel A. Goldstein, et al.
Published: (2020-07-01)

The utility of the 21-gene Oncotype DX Breast Recurrence Score® assay in node-negative breast cancer patients – the final analysis of the Polish real life survey PONDx
by: Michał Jarząb, et al.
Published: (2024-10-01)

Correlations Between Oncotype DX Recurrence Score and Classic Risk Factors in Early Breast Cancer: Results of A Prospective Multicenter Study in Turkey
by: Vahit Özmen, et al.
Published: (2016-07-01)

The Oncotype Dx Assay in ER-Positive, HER2-Negative Breast Cancer Patients: A Real Life Experience from a Single Cancer Center
by: Stephane Thibodeau, et al.
Published: (2019-07-01)

Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer
by: McVeigh TP, et al.
Published: (2017-05-01)

Correlation analysis between mammography features of early-stage invasive breast ductal carcinoma with positive ER, negative HER2, negative lymph node and Oncotype DX21 gene assay results
by: WANG Ting , LIU Zhuang , GONG Jing , JIANG Lin , SHEN Xigang , GU Yajia
Published: (2021-06-01)

Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score® Test from a US Societal Perspective
by: Berdunov V, et al.
Published: (2024-06-01)

Budget impact of the Oncotype DX® test compared to other gene expression tests in patients with early breast cancer in Germany
by: M.P. Lux, et al.
Published: (2022-01-01)

The ZNF217 Biomarker Predicts Low- and High-Risk Oncotype DX® Recurrence Score in ER-Positive Invasive Breast Cancers
by: Pascale A. Cohen, et al.
Published: (2019-05-01)

Is Oncotype DX testing informative for breast cancers with low ER expression? A retrospective review from a biomarker testing referral center
by: John Loggie, et al.
Published: (2024-06-01)

Survival results according to Oncotype Dx recurrence score in patients with hormone receptor positive HER-2 negative early-stage breast cancer: first multicenter Oncotype Dx recurrence score survival data of Turkey
by: Çağlar Ünal, et al.
Published: (2023-06-01)

Population-based estimate for the correlation of the Oncotype Dx Breast Recurrence Score® result and Ki-67 IHC MIB-1 pharmDx in HR+, HER2−, node-positive early breast cancer
by: Michael Crager, et al.
Published: (2022-11-01)

Deep Learning-Based Pathology Image Analysis Enhances Magee Feature Correlation With Oncotype DX Breast Recurrence Score
by: Hongxiao Li, et al.
Published: (2022-06-01)

A 10 year service evaluation of the survival of 439 patients with early oestrogen receptor positive breast cancer who underwent initial OncotypeDX ® testing to guide adjuvant chemotherapy decisions
by: Asma Munir, et al.
Published: (2023-01-01)

Association between pathological characteristics and recurrence score by OncotypeDX in resected T1-3 and N0-1 breast cancer: a real-life experience of a North Hungarian regional center
by: Dániel Deme, et al.
Published: (2024-04-01)

The impact of extensive intraductal component (EIC) on the genomic risk of recurrence in early hormone receptor positive breast cancer
by: Yael Bar, et al.
Published: (2024-10-01)

Does Pre-Emptive Availability of PREDICT 2.1 Results Change Ordering Practices for Oncotype DX? A Multi-Center Prospective Cohort Study
by: Arif Ali Awan, et al.
Published: (2024-02-01)

The Correlation of Magee EquationsTM and Oncotype DX® Recurrence Score From Core Needle Biopsy Tissues in Predicting Response to Neoadjuvant Chemotherapy in ER+ and HER2- Breast Cancer
by: Atilla Soran, et al.
Published: (2020-04-01)

Corrigendum: Association between pathological characteristics and recurrence score by OncotypeDX in resected T1-3 and N0-1 breast cancer: a real-life experience of a North Hungarian regional center
by: Dániel Deme, et al.
Published: (2024-07-01)

Lymphovascular invasion in hormone-positive, human epidermal growth factor-negative, low-burden axillary disease in early breast cancer patients tested for oncotype DX recurrence score
by: Abdalla Saad Abdalla Al-Zawi, et al.
Published: (2022-07-01)

New Approaches in Breast Cancer Radiotherapy
by: Niyazi Volkan Demircan, et al.
Published: (2024-01-01)

The evolution of gene expression profiling in breast cancer – A narrative review
by: Banushree Chandrasekhar Srinivasamurthy
Published: (2023-01-01)

Prospective observational study on the impact of the 21-gene assay on treatment decisions and resources optimization in breast cancer patients in Lombardy: The BONDX study
by: Alberto Zambelli, et al.
Published: (2020-08-01)

The Role of the 21-Gene Recurrence Score<sup>®</sup> Assay in Hormone Receptor-Positive, Node-Positive Breast Cancer: The Canadian Experience
by: Mariya Yordanova, et al.
Published: (2022-03-01)

Unified model involving genomics, magnetic resonance imaging and prostate‐specific antigen density outperforms individual co‐variables at predicting biopsy upgrading in patients on active surveillance for low risk prostate cancer
by: Alp Tuna Beksac, et al.
Published: (2022-03-01)

Correlation of Ki-67 proliferative index with oncotype DX recurrence score in hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer with low-burden axillary nodal disease – a review of 137 cases
by: Abdalla Saad Abdalla Al-Zawi, et al.
Published: (2024-03-01)

Clinical Utility of Multigene Profiling Assays in Early-Stage Invasive Breast Cancer: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline
by: Phillip Blanchette, et al.
Published: (2022-04-01)

Oncotype DX Breast Recurrence Score Distribution and Chemotherapy Benefit Among Women of Different Age Groups With HR-Positive, HER2-Negative, Node-Negative Breast Cancer in the SEER Database
by: Ran Cheng, et al.
Published: (2020-10-01)

Impact of the OncotypeDX score and HER2 RNA PCR levels on HER2-low IHC levels in primary and metastasized tumors
by: Didi Feldman, et al.
Published: (2023-10-01)

Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10)
by: Bernhard C. Pestalozzi, et al.
Published: (2017-04-01)

Cost effectiveness of Gene Expression Profiling in Patients with Early-Stage Breast Cancer in a Middle- Income Country, Turkey: Results of a Prospective Multicenter Study
by: Vahit Özmen, et al.
Published: (2019-07-01)

Lymphovascular invasion is an independent prognostic factor in breast cancer irrespective of axillary node metastasis and molecular subtypes
by: Suk Jun Lee, et al.
Published: (2023-11-01)

NURR1 Is Differentially Expressed in Breast Cancer According to Patient Racial Identity and Tumor Subtype
by: Shahensha Shaik, et al.
Published: (2022-12-01)

MCM-2 Levels as a Potential Biomarker for Predicting High-Risk Breast Cancer Patients According to TAILORx Classification
by: Ünal Ç, et al.
Published: (2023-09-01)

Assessment High-Risk Breast Cancer in Older Patients: A Comparative Analysis of PREDICT Scores and TAILORx Risk Categorization
by: Çağlar Ünal, et al.
Published: (2023-10-01)

Favorable locoregional control in clinically node-negative hormone-receptor positive breast cancer with low 21-gene recurrence scores: a single-institution study with 10-year follow-up
by: Cihan Uras, et al.
Published: (2022-11-01)